MIM
NVCR icon

Macroview Investment Management’s NovoCure NVCR Stock Holding History

Macroview Investment Management’s Portfolio NVCR Stock Details NVCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-539
Closed -$8.43K – 384
2024
Q3 		$8.43K Buy
539
+140
+35% +$2.54K 0.01% 311
2024
Q2 		$6.83K Buy
+399
New +$7.02K 0.01% 332
2020
Q2 		– Sell
-40
Closed -$3K – 371
2020
Q1 		$3K Buy
+40
New +$3.16K 0.01% 184

Other funds holding NVCR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Macroview Investment Management's NVCR Position: Q4 2024 in Review

Macroview Investment Management sold out of NovoCure (NVCR) in Q4 2024, closing a stake of 539 shares — an estimated $8.43K sold.

Macroview Investment Management first reported a position in NVCR in Q1 2020 and held it in 3 quarters. The position peaked at $8.43K in Q3 2024. 238 funds tracked by Wall St. Rank hold NVCR as of Q4 2024.

  • Macroview Investment Management reported no remaining NovoCure position as of Q4 2024 after selling out during the quarter.
  • Macroview Investment Management sold 539 NovoCure shares in Q4 2024, an estimated $8.43K.
  • Macroview Investment Management first reported a position in NovoCure in Q1 2020 and held it in 3 quarters.
  • Macroview Investment Management's NovoCure position peaked at $8.43K in Q3 2024.
  • 238 funds tracked by Wall St. Rank held NovoCure as of Q4 2024.

Based on Macroview Investment Management's 13F filing for Q4 2024, filed 31 Jan 2025.